M. C. Boon

Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial

Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer

Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection

Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) - gastrointestinal cancer group

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

Gastric cancer

Risk factors for surgical treatment in the Dutch gastric cancer trial

Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer

Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer

Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction

Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers

Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial

Overview of Adjuvant Therapy for Resected Gastric Cancer: Differences in Japan and the United States

Potential and Futility of Sentinel Node Detection for Gastric Cancer

Extended Lymph-Node Dissection for Gastric Cancer

Effects of fixation method on image cytometric measurement of DNA content and distribution in cells stained for fluorescence with propidium iodide.

Sentinel Lymph Node Mapping of the Gastrointestinal Tract by Using Invisible Light

Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine

Oesophageal carcinoma

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

Guidelines for the management of oesophageal and gastric cancer

An updated meta-analysis of adjuvant chemotherapy after curative resection for gastric cancer

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

Gastric cancer

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Tumor Heterogeneity and Immunotherapy of Cancer

CellProfiler: image analysis software for identifying and quantifying cell phenotypes

Bladder cancer: Epidemiology, staging and grading, and diagnosis

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

Prognostic factors in pT _a ‐pT ₁ superficial bladder tumours treated with intravesical instillations

Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries.

Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients

Kinetic parameters for small-molecule drug delivery by covalent cell surface targeting

Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancer

Quality control of lymph node dissection in the Dutch Gastric Cancer Trial

Randomized Multicenter Phase II Trial of a Biweekly Regimen of Fluorouracil and Leucovorin (LV5FU2), LV5FU2 Plus Cisplatin, or LV5FU2 Plus Irinotecan in Patients With Previously Untreated Metastatic Gastric Cancer: A Fédération Francophone de Cancérologie Digestive Group Study—FFCD 9803

Chemotherapy for advanced gastric cancer

Disparities in Gastric Cancer Chemotherapy Between the East and West

Optimal Locoregional Treatment in Gastric Cancer

Management of Gastroesophageal Tumors

Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer

Evaluation of the extent of lymphadenectomy in a randomized trial of Western- versus Japanese-type surgery in gastric cancer.

Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials.

Morphometry, densitometry and pattern analysis of plastic-embedded histologic material from urothelial cell carcinoma of the bladder.